featured
FOLFOXIRI–Bevacizumab or FOLFOX–Panitumumab in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Propensity Score-Based Analysis
Oncologist 2020 Dec 18;[EPub Ahead of Print], F Pietrantonio, G Fucà, D Rossini, HJ Schmoll, JC Bendell, F Morano, C Antoniotti, S Corallo, B Borelli, A Raimondi, F Marmorino, M Niger, A Boccaccino, G Masi, S Lonardi, L Boni, F de Braud, M Di Bartolomeo, A Falcone, C CremoliniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.